



Sponsored by the  
American Society of Addiction Medicine,  
ASAM Region X

BUPRENORPHINE AND  
OFFICE-BASED TREATMENT  
OF OPIOID  
DEPENDENCE



SATURDAY, JULY 17, 2004  
7:00 AM - 5:30 PM

BEAU RIVAGE  
875 Beach Boulevard  
Biloxi, Mississippi

Physicians who complete this course will be eligible to  
request a waiver to practice medication-assisted addiction  
therapy with Buprenorphine, for the treatment of  
opioid dependence.

[www.samhsa.gov](http://www.samhsa.gov) | [www.asam.org](http://www.asam.org) |  
[www.buprenorphine.samhsa.gov](http://www.buprenorphine.samhsa.gov)

PROGRAM GOALS & OBJECTIVES

After participating in this course, participants should be  
better able to describe:

- The prerequisites for a physician to begin to prescribe  
buprenorphine in office-based practice
- The clinically relevant pharmacological characteristics  
of buprenorphine
- Factors to consider in determining if a patient is an  
appropriate candidate for office-based treatment
- Induction and maintenance protocols
- Strategies for integrating psychosocial care with  
office-based pharmacological treatment
- Treatment strategies for management of chronic and  
acute pain in patients in maintenance treatment for  
opioid dependence

The Drug Addiction Treatment Act of 2000 (PL106-  
310, Section 3502) permits physicians who are  
trained or experienced in opioid addiction treatment  
to obtain waivers to prescribe certain narcotic drugs  
in Schedule III, IV, or V of the Controlled Substances  
Act, in their office practices or in a clinic setting, for the  
treatment of opioid dependence. Both buprenorphine  
and the combination of buprenorphine with naloxone  
are approved by FDA for use in detoxification and  
maintenance treatment of opioid dependence.

Physicians are qualified if they are certified in Addiction  
Medicine or Addiction Psychiatry. As part of the  
requirements to obtain the waiver, physicians not  
otherwise qualified must complete not less than 8 hours  
of training. Physicians who complete this 8-hour course  
will meet the training qualification under the new law and  
will receive a certificate of attendance suitable to send  
to the Secretary of HHS along with the request for the  
waiver. If you give ASAM permission to do so, ASAM will  
report your name directly to the Secretary of HHS within  
4 weeks of the program, if you have attended the full 8  
hours, eliminating the need for you to send the certificate  
of attendance.

Because ASAM will be called upon to confirm that  
participants have attended a full 8 hours, you must  
bring a photo identification to show as part of the  
sign-in process; you must confirm your attendance  
with your signature at the beginning of both the  
morning and the afternoon sessions; and you must  
sign out at the conclusion of the program.

Certificates of attendance will be mailed to you within  
4 weeks of the program. Note that latecomers will not  
be eligible for a certificate of attendance if ASAM cannot  
confirm 8 hours of attendance.

PROGRAM OVERVIEW

WHO SHOULD ATTEND

This program is recommended for physicians with  
experience and/or interest in treating opioid dependence.  
This program is also recommended for primary care,  
psychiatric, HIV and addiction medicine physicians.

CONTINUING MEDICAL EDUCATION CREDIT

The American Society of Addiction Medicine is accredited  
by the Accreditation Council for Continuing Medical  
Education to provide continuing medical education  
for physicians.

The American Society of Addiction Medicine (ASAM)  
designates this continuing medical education activity  
for up to 8 hours in Category 1 credit towards the AMA  
Physician's Recognition Award. Each physician should  
claim only those hours of credit that he/she actually  
spent in the educational activity.

Supported by an unrestricted continuing medical education  
grant provided by Reckitt Benckiser.

